A study from Karolinska Institutet, Stockholm, Sweden shows that “MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool.”
This study was published in the April 10, 2014 Nature [I.F >42] by Prof. Thomas H, Dr Gad H and others from Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-Chief-Scientist of GBMD, reports here that: Natural product-based cancer therapy: γ-Bisabolene, one of the main components of Cardamom, inhibits cancer development by suppressing the expression of nucleotide sanitizing enzyme MTH1/NUDT1.
Significance:
This study suggests that γ-Bisabolene, by up-regulating its target gene, it may suppress the expression of MTH1/NUDT1. Thus, pharmacological formulations encompassing “γ-Bisabolene or its analogues” may be used in the treatment of human cancers.
γ-Bisabolene inhibits human cancer development via down-regulation of MTH1/NUDT1
γ-Bisabolene
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org or http://newbioideas.com
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Amount: $200*
Undisclosed information: How γ-Bisabolene suppresses the expression of MTH1/NUDT1
Results guaranteed if not refunded
To cite: Boominathan, Natural product-based cancer therapy: γ-Bisabolene, one of the main components of Cardamom, inhibits cancer development by suppressing the expression of nucleotide sanitizing enzyme MTH1/NUDT1, 11/October/2016, 10.15 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
# Research cooperation